Cargando…

Advances in NK cell therapy for brain tumors

Despite advances in treatment regimens that comprise surgery, chemotherapy, and radiation, outcome of many brain tumors remains dismal, more so when they recur. The proximity of brain tumors to delicate neural structures often precludes complete surgical resection. Toxicity and long-term side effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Fares, Jawad, Davis, Zachary B., Rechberger, Julian S., Toll, Stephanie A., Schwartz, Jonathan D., Daniels, David J., Miller, Jeffrey S., Khatua, Soumen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932101/
https://www.ncbi.nlm.nih.gov/pubmed/36792722
http://dx.doi.org/10.1038/s41698-023-00356-1
_version_ 1784889375894536192
author Fares, Jawad
Davis, Zachary B.
Rechberger, Julian S.
Toll, Stephanie A.
Schwartz, Jonathan D.
Daniels, David J.
Miller, Jeffrey S.
Khatua, Soumen
author_facet Fares, Jawad
Davis, Zachary B.
Rechberger, Julian S.
Toll, Stephanie A.
Schwartz, Jonathan D.
Daniels, David J.
Miller, Jeffrey S.
Khatua, Soumen
author_sort Fares, Jawad
collection PubMed
description Despite advances in treatment regimens that comprise surgery, chemotherapy, and radiation, outcome of many brain tumors remains dismal, more so when they recur. The proximity of brain tumors to delicate neural structures often precludes complete surgical resection. Toxicity and long-term side effects of systemic therapy remain a concern. Novel therapies are warranted. The field of NK cell-based cancer therapy has grown exponentially and currently constitutes a major area of immunotherapy innovation. This provides a new avenue for the treatment of cancerous lesions in the brain. In this review, we explore the mechanisms by which the brain tumor microenvironment suppresses NK cell mediated tumor control, and the methods being used to create NK cell products that subvert immune suppression. We discuss the pre-clinical studies evaluating NK cell-based immunotherapies that target several neuro-malignancies and highlight advances in molecular imaging of NK cells that allow monitoring of NK cell-based therapeutics. We review current and ongoing NK cell based clinical trials in neuro-oncology.
format Online
Article
Text
id pubmed-9932101
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-99321012023-02-17 Advances in NK cell therapy for brain tumors Fares, Jawad Davis, Zachary B. Rechberger, Julian S. Toll, Stephanie A. Schwartz, Jonathan D. Daniels, David J. Miller, Jeffrey S. Khatua, Soumen NPJ Precis Oncol Review Article Despite advances in treatment regimens that comprise surgery, chemotherapy, and radiation, outcome of many brain tumors remains dismal, more so when they recur. The proximity of brain tumors to delicate neural structures often precludes complete surgical resection. Toxicity and long-term side effects of systemic therapy remain a concern. Novel therapies are warranted. The field of NK cell-based cancer therapy has grown exponentially and currently constitutes a major area of immunotherapy innovation. This provides a new avenue for the treatment of cancerous lesions in the brain. In this review, we explore the mechanisms by which the brain tumor microenvironment suppresses NK cell mediated tumor control, and the methods being used to create NK cell products that subvert immune suppression. We discuss the pre-clinical studies evaluating NK cell-based immunotherapies that target several neuro-malignancies and highlight advances in molecular imaging of NK cells that allow monitoring of NK cell-based therapeutics. We review current and ongoing NK cell based clinical trials in neuro-oncology. Nature Publishing Group UK 2023-02-15 /pmc/articles/PMC9932101/ /pubmed/36792722 http://dx.doi.org/10.1038/s41698-023-00356-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Fares, Jawad
Davis, Zachary B.
Rechberger, Julian S.
Toll, Stephanie A.
Schwartz, Jonathan D.
Daniels, David J.
Miller, Jeffrey S.
Khatua, Soumen
Advances in NK cell therapy for brain tumors
title Advances in NK cell therapy for brain tumors
title_full Advances in NK cell therapy for brain tumors
title_fullStr Advances in NK cell therapy for brain tumors
title_full_unstemmed Advances in NK cell therapy for brain tumors
title_short Advances in NK cell therapy for brain tumors
title_sort advances in nk cell therapy for brain tumors
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932101/
https://www.ncbi.nlm.nih.gov/pubmed/36792722
http://dx.doi.org/10.1038/s41698-023-00356-1
work_keys_str_mv AT faresjawad advancesinnkcelltherapyforbraintumors
AT daviszacharyb advancesinnkcelltherapyforbraintumors
AT rechbergerjulians advancesinnkcelltherapyforbraintumors
AT tollstephaniea advancesinnkcelltherapyforbraintumors
AT schwartzjonathand advancesinnkcelltherapyforbraintumors
AT danielsdavidj advancesinnkcelltherapyforbraintumors
AT millerjeffreys advancesinnkcelltherapyforbraintumors
AT khatuasoumen advancesinnkcelltherapyforbraintumors